On 02/05/2026 a federal appeals court granted a request by the state of Louisiana to restore an old requirement that the abortion medication mifepristone be dispensed only in person. The ruling effectively bars routine distribution of the drug via telehealth consultations and mail delivery across the United States, reversing policies that many clinics, pharmacies and patients have relied upon for years. The decision arrived amid ongoing legal challenges and was met immediately with an emergency appeal to the supreme court by Danco Laboratories, the only company that markets the branded product in the U.S.
The disruption prompted statements from reproductive health groups, manufacturers and state officials alike, and raised urgent questions about the ability of patients in restrictive states to access care. The appeal asks the high court to issue a temporary stay — a legal pause — so existing distribution practices can continue while appeals proceed. Both sides frame their positions around safety, legal precedent and the balance between federal regulatory authority and state law.
What the appeals court ordered and why it matters
The panel of the Fifth Circuit sided with Louisiana in reinstating a decades-old requirement that mifepristone be provided in person. Louisiana argued that the change undermines the state’s abortion restrictions and increases potential costs to Medicaid for emergency care allegedly tied to the drug. The appellate opinion asserted that Louisiana had shown it was likely to succeed on the merits and that it faced irreparable harm without the injunction. The ruling is significant because it applies nationwide, meaning a single state’s challenge altered distribution rules used across the country.
How prior federal actions set the stage
During the Covid pandemic, the Food and Drug Administration temporarily allowed the mailing of mifepristone and prescriptions via telehealth to reduce in-person contacts. In 2026, the FDA made that temporary policy permanent, formalizing what many providers had used to serve patients in states where in-clinic care is limited. The availability of telehealth and mail prescriptions has been a vital pathway for people living under strict state bans to obtain medication abortions, which now account for more than half of all abortions in the United States.
Danco’s emergency appeal and the company’s arguments
Within hours of the Fifth Circuit’s order, Danco Laboratories filed for an immediate administrative stay with the Supreme Court and sought at least a one-week pause from the appeals court. In its filings the company stressed that the appellate order abruptly reversed distribution conditions that had been in place for over five years and that this sudden change was unprecedented. Danco also warned of irreparable harm to its business: Mifeprex is the company’s only marketed product, and cutting off nationwide telehealth and mail distribution, it argued, threatens the company’s survival and revenue stream.
Legal and practical claims
Lawyers for Danco framed the request as both a legal and practical emergency. They argued that the FDA‘s regulatory framework had provided a stable basis for distribution and that the appellate order risks immediate confusion at pharmacies and clinics nationwide. The company asked the Supreme Court to prevent what it described as chaos while courts adjudicate complex questions about agency authority, standing, and the proper reach of state challenges to federal drug approvals.
Reactions and wider implications
Reproductive health advocates and manufacturers of generic versions of the drug responded sharply to the appeals court decision. Organizations such as Planned Parenthood described the move as a setback for patient access and safety, noting the long record of peer-reviewed research showing medication abortions are generally safe and effective. Generic manufacturers and other stakeholders said they were reviewing the order and considering their options to keep the drug accessible. Opponents of abortion hailed the ruling as a lawful defense of state protections for fetuses and a correction to what they called lax federal policy.
Broader legal landscape
The case sits within a broader set of lawsuits challenging FDA actions dating back to the drug’s initial approval roughly 26 years ago, and other states have pursued similar challenges. Two years ago the Supreme Court declined to permit a separate challenge to nationwide access to continue because the challengers lacked standing, leaving distribution intact at that time. The current flurry of litigation raises unresolved issues about federal agency authority, the ability of a single state to obtain nationwide relief, and how courts should weigh public interest and equity when health care access is at stake.
As the appeal moves toward the Supreme Court, patients, providers and companies face near-term uncertainty about access and operations. The high court’s willingness to intervene quickly could determine whether existing telehealth and mail pathways for mifepristone remain available while the legal battles play out, or whether new constraints will reshape medication abortion access across many states.
